Monitoring of treatment response to the CAIX/CAXII inhibitor SLC-0111, which currently is in phase Ib/II clinical trials for adult solid cancers [29], is performed with isothermal microcalorimetry of the intact tumor tissue. Here, CA9 is linked to neoplasm.